<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45291">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01990326</url>
  </required_header>
  <id_info>
    <org_study_id>XAF5 B1</org_study_id>
    <nct_id>NCT01990326</nct_id>
  </id_info>
  <brief_title>Phase 2a Study of XAF5 Gel for Reduction of Submental Fat</brief_title>
  <official_title>A Phase 2a, Randomized, Double-blind, Placebo-controlled Study of XAF5 Gel for Reduction of Submental Fat</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Topokine Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Topokine Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test the effects of XAF5 Gel (applied to skin each night for 6 weeks) on
      excess submental fat, also known as double chin.  The study will also assess the safety and
      tolerability of XAF5 Gel.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in submental fat volume</measure>
    <time_frame>From Day 0 to Day 43</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>From Day 1 to Day 57</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Excess Submental Fat (&quot;Double Chin&quot;)</condition>
  <arm_group>
    <arm_group_label>XAF5 Gel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patient will apply XAF5 Gel to the skin of the submental area once a night.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Gel</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patient will apply a Placebo Gel to the skin of the submental area once a night.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>XAF5 Gel</intervention_name>
    <arm_group_label>XAF5 Gel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Gel</intervention_name>
    <arm_group_label>Placebo Gel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (paraphrased):

          -  Adult men and women

          -  Must understand and provide informed consent

          -  Moderate submental fat (as determined by the clinician)

          -  No laxity (looseness) or minimal laxity of submental skin

          -  Healthy skin upon which a skin reaction would be visible

        Exclusion Criteria (paraphrased):

          -  A clinically significant health problem or recent illness

          -  A clinically significant abnormal result on physical exam or laboratory tests

          -  Neck or facial hair that would interfere with applying the study drug to submental
             skin

          -  Clinically significant skin disease

          -  Body Mass Index (BMI) &gt;= 40

          -  Plan to begin a diet or weight loss regimen during the study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael S Singer, M.D., Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>Topokine Therapeutics</affiliation>
  </overall_official>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 10, 2014</lastchanged_date>
  <firstreceived_date>November 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
